inPractice® - SPRING-2 and SINGLE Trials

Special Considerations in the Management of HIV-Infected Patients From Minority Communities

Authors: Bisola Ojikutu, MD, MPH; Valerie E. Stone, MD, MPH (More Info)
Section Editor: Judith S. Currier, MD, MSc
Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
Last Reviewed: 7/9/18 (What's New)

Summary

SPRING-2 trial compared dolutegravir with raltegravir in treatment-naive patients receiving coformulated emtricitabine/tenofovir DF or abacavir/lamivudine^{[Raffi 2013]}
SINGLE trial compared dolutegravir plus coformulated abacavir/lamivudine with efavirenz/emtricitabine/tenofovir DF in treatment-naive patients^{[Walmsley 2013]}
Efficacy of the dolutegravir-based regimens was similar across racial groups^{[Raffi 2015]}

Action required

Login now to access all of your entitled content
or
View additional options to gain access to this content

Keywords: Initial Antiretroviral Therapy, Minority-Ethnic Communities, Pharmacokinetics, Special Populations